Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-12-13
2002-07-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S392000
Reexamination Certificate
active
06426347
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to certain 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them. It also relates to the use of such compounds in the treatment or prevention of psychotic disorders such as schizophrenia and other central nervous system diseases. The use of the compounds of this invention to the treatment of these disorders is indicated by the ability of the compounds to bind selectively to dopamine receptor subtypes.
2. Description of the Related Art
The therapeutic effect of conventional antipsychotics, known as neuroleptics, is generally believed to be exerted through blockade of dopamine receptors. However, neuroleptics are frequently responsible for undesirable extrapyramidal side effects (EPS) and tardive dyskinesias, which are attributed to blockade of D2 receptors in the striatal region of the brain. The dopamine D4 receptor subtype has recently been identified (Van Tol, H. H. et al.,
Nature,
1991, 350, 610). Its unique localization in limbic brain areas and its differential recognition of various antipsychotics suggest that the D4 receptor play a role in the etiology of schizophrenia. Selective D4 antagonists are effective antipsychotics free from the neurological side effects displayed by conventional neuroleptics.
Since dopamine D4 receptors are concentrated in the limbic system which controls cognition and emotion, compounds which interact with these receptors have utility in the treatment of cognitive disorders. Such disorders include the cognitive deficits which are a significant component of the negative symptoms (social withdrawal and unresponsiveness) of schizophrenia. Other disorders involving memory impairment or attention deficit disorders can also be treated with compounds that interact specifically with the dopamine D4 receptor subtype.
Japanese patent JP 47017306 discloses m-trifluoromethylphenyl benzyl piperazines as tranquilizers and analgetic agents. Nucl. Med. Biol. 20(6), 777-94, 1993, discloses radiolabelled 1-([4-{fluoro-18F}phenyl]methyl)-4-(3-[trifluoromethyl]phenylpiperazine as an imaging agent.
J. Med. Chem. 37, 1060-1062, 1994, and International Application No. WO 9304684 discloses 4-arylpiperazines and 4-arylpiperidines.
J. Med. Chem. 11, 1144-1150, 1968, discloses certain 1-phenyl-4-benzyl piperazines as antihypertensive agents.
SUMMARY OF THE INVENTION
This invention provides novel compounds of Formula I which interact with dopamine receptor subtypes. Accordingly, a broad embodiment of the invention is directed to a compound of Formula I:
or the pharmaceutically acceptable addition salts thereof wherein:
R
1
is halogen or C
1
-C
4
alkyl; and
R
2
and R
3
are the same or different and represent hydrogen, halogen, C
1
-C
4
alkyl, C
1
-C
4
alkoxy, alkylthio, hydroxy, amino, mono(C
1
-C
4
)alkylamino, di(C
1
-C
4
)alkylamino, or
R
2
and R
3
together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety.
The compounds of the present invention demonstrate high affinity and selectivity in binding to the Dopamine D4 receptor subtype. Consequently, they are useful in the treatment of schizophrenia, psychotic depression and mania Other dopamine-mediated diseases such as Parkinsonism and tardive dyskinesias can also be treated directly or indirectly by modulation of D4 receptors. Compounds of the invention are also useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents as well as in the treatment of other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorder.
Furthermore, compounds of this invention are useful in treating depression, memory-impairment or Alzheimer's disease by modulation of D4 receptors which selectively exist in limbic areas known to control emotion and cognitive functions. The interaction of 1-phenyl-4-benzylpiperazines with dopamine receptor subtypes is shown. This interaction results in the pharmacological activities of these compounds.
The invention further provides pharmaceutical compositions comprising compounds of Formula I. It also relates to the use of such compounds and compositions in the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, dystonia, compulsive behavior, substance abuse, memory impairment, cognitive deficits, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
DETAILED DESCRIPTION OF THE INVENTION
As mentioned above, the invention encompasses substituted 1-Phenyl-4-benzylpiperazines of formula I. Preferred compounds of formula I are those where R
2
and R
3
may not be 2-isopropoxyl and hydrogen, respectively, when R
1
is bromo.
The invention also encompasses compounds of formula II:
wherein
R
x
is fluorine, chlorine, bromine, or iodine; and
R
2
and R
3
are the same or different and represent hydrogen, halogen, C
1
-C
4
alkyl, C
1
-C
4
alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino.
In preferred embodiments of formula II, R
2
and R
3
may not be 2-isopropoxyl and hydrogen, respectively, when R
1
is bromo. More preferred compounds of formula II are those where R
x
is chloride; R
2
and R
3
may not be 2-isopropoxyl and hydrogen, respectively, when R
1
is bromo; R
2
is halogen, most preferably chloride, or methyl or methoxy; and R
3
is hydrogen or methyl.
The invention also encompasses compounds of formula III:
wherein
R
a
is C
1
-C
4
alkyl; and
R
2
and R
3
are the same or different and represent hydrogen, halogen, C
1
-C
4
allyl, C
1
-C
4
alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino.
In preferred embodiments of formula III, R
a
is methyl; R
2
is halogen, most preferably chloride, or methyl or methoxy; and R
3
is hydrogen or methyl.
Particularly preferred compounds of formulas II and III are those where the phenyl group substituted with R
2
and/or R
3
is selected from the group consisting of:
The invention also encompasses compounds of formula VI:
wherein
R
1
is C
1
-C
4
alkyl or halogen.
Preferred compounds of formula VI are those where R
a
is methyl, Cl, or F.
The invention also encompasses a method for treating or preventing neuropsychological disorders such as, for example, schizophrenia and other central nervous system diseases which comprises administering to a patient in need of such treatment a compound of the invention.
Representative compounds of the present invention, which are encompassed by Formula I, include, but are not limited to the compounds in Table I and their pharmaceutically acceptable salts. Non-toxic pharmaceutically acceptable salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanoic such as acetic, HOOC—(CH
2
)
n
—COOH where n is 0-4, and the like. Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable addition salts.
The present invention also encompasses the acylated prodrugs of the compounds of Formula I. Those skilled in the art will recognize various synthetic methodologies which may be employed to prepare non-toxic pharmaceutically acceptable addition salts and acylated prodrugs of the compounds encompassed by Formula I.
By the terms C
1
-C
4
alkyl and lower alkyl is meant straight and branched chain alkyl groups having from 1-4 carbon atoms as well as cyclic alkyl groups such as, for example, cyclopropyl and cyclobutyl. Specific examples of such alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and sec-butyl. Preferred C
1
-C
4
alkyl groups are methyl and ethyl.
By the terms C
1
-C
4
alkoxy and lower alkoxy is meant straight and branched chain alkoxy groups having from 1-4 carbon atoms.
By the term alkylthio is meant lower alkyl groups bound to the parent sys
Chen Xi
Thurkauf Andrew
Bernhardt Emily
McDonnell & Boehnen Hulbert & Berghoff
Neurogen Corporation
LandOfFree
1-phenyl-4-benzylpiperazines dopamine receptor subtype... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-phenyl-4-benzylpiperazines dopamine receptor subtype..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-phenyl-4-benzylpiperazines dopamine receptor subtype... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2907171